American molecular biologists have developed a highly effective personalized vaccine against glioblastoma, one of the most aggressive forms of brain cancer.
Thanks to the new approach, a patient diagnosed with stage 4 cancer survived more than five years.
According to Washington State University, the vaccine analyzes proteins in each patient's tumor cells to create tailored therapy.
In trials on 9 volunteers, tumor growth stopped in 66% of patients. One-third lived over two years, and one patient completely recovered.
With about 300,000 cases diagnosed annually worldwide, the vaccine offers hope for this deadly disease.
